• Ticker

    Advertisement Find a Broker - Visit the DailyFinance Broker Center
DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$2.71 -$0.05 (-1.81%)

REAL-TIME: Last trade at

Albany Molecular Research, Inc...

NASDAQ:AMRI

Jump to this page for:

Related Resources

AMRI Announces President for AMRI Europe

5/22/2012 by PR Newswire

Albany Molecular Research (AMRI) Misses Q1 EPS by 3c

5/9/2012 by StreetInsider.com

Albany Molecular reports Q1 EPS (13c), one estimate 5c

5/9/2012 by Theflyonthewall.com

Albany Molecular sees FY12 EPS 6c-12c, one estimate 9c

5/9/2012 by Theflyonthewall.com

AMRI Announces First Quarter 2012 Results

5/9/2012 by PR Newswire

AMRI Launches SMARTSOURCING™ For Contract Manufacturing and Research Services

4/30/2012 by PR Newswire

AMRI Hires Director of In Vitro Biology in Singapore

4/26/2012 by PR Newswire

AMRI Strengthens Business Development and Marketing Groups

4/24/2012 by PR Newswire

AMRI Announces Development and Manufacturing Deal with Biota Holdings Limited

4/17/2012 by PR Newswire

Albany Molecular announces development, manufacturing deal with Biota

4/17/2012 by Theflyonthewall.com

Albany Molecular signs exclusive option to enter license agreement with Bessor

4/3/2012 by Theflyonthewall.com

AMRI Signs Exclusive Option to License its Tubulin Inhibitor Program for Cancer

4/3/2012 by PR Newswire

AMRI CFO to Present at 11th Annual Needham Healthcare Conference

3/28/2012 by PR Newswire

AMRI Hires Senior Manager to Oversee Facilities at Burlington Aseptic Fill Operations

3/27/2012 by PR Newswire

Albany Molecular Research, Inc. (AMRI) to Close Hungary Unit, Cut 100 Jobs

3/22/2012 by BioSpace

Albany Molecular (AMRI) to Cease Operations in Budapest

3/21/2012 by StreetInsider.com

Albany Molecular sees 2012 contract gross margin 45-8%

2/7/2012 by Theflyonthewall.com

Albany Molecular 2012 R&D expense will decrease approximately $1M

2/7/2012 by Theflyonthewall.com

Albany Molecular sees Q1 Allegra royalties $10M-$12M

2/7/2012 by Theflyonthewall.com

Albany Molecular Q4 total contract revenue $39.4M

2/7/2012 by Theflyonthewall.com

Albany Molecular reports Q4 adjusted EPS (19c) vs. consensus (12c)

2/7/2012 by Theflyonthewall.com

AMRI Announces Fourth Quarter and Full Year 2011 Results

2/7/2012 by PR Newswire

Albany Molecular U.K. facility gets MHRA GMP certification

1/18/2012 by Theflyonthewall.com

MHRA Issues GMP Certification to AMRI UK Facility

1/18/2012 by PR Newswire

AMRI Announces Review of Its Hungary Operation

1/9/2012 by PR Newswire

Royce & Associates reports 5.31% passive stake in Albany Molecular

1/5/2012 by Theflyonthewall.com

Albany Molecular nnounces preferred provider agreement with BioPontis Alliance

1/5/2012 by Theflyonthewall.com

AMRI Announces Preferred Provider Agreement with BioPontis Alliance LLC

1/5/2012 by PR Newswire

Albany Molecular Research, Inc. (AMRI) Cuts Jobs in Q4

12/28/2011 by BioSpace

Albany Molecular to reduce workforce in 2012

12/22/2011 by Theflyonthewall.com

Albany Molecular (AMRI) Files $50M Mixed Shelf

12/22/2011 by StreetInsider.com

Albany Molecular (AMRI) Announces Workforce Reduction, to Cease Facility Lease; Updates on Expected Charges

12/22/2011 by StreetInsider.com

AMRI Announces Additional Actions to Streamline Operations

12/22/2011 by Business Wire

Albany Molecular files $50M mixed securities shelf

12/22/2011 by Theflyonthewall.com

Weekly CFO Buys Highlight: TSON, PRTS, FXCM, AMRI, MN

12/5/2011 by GuruFocus

Albany Molecular catalysts may drive shares materially higher, says Sterne Agee

12/5/2011 by Theflyonthewall.com

Albany Molecular management to meet with Sterne Agee

11/28/2011 by Theflyonthewall.com

Sterne Agee Downgrades Albany Molecular Research (AMRI) to Buy

11/15/2011 by StreetInsider.com

Albany Molecular initiated with a Buy at Sterne Agee

11/15/2011 by Theflyonthewall.com

The Recent Drop In Albany Molecular's Stock Price May Be Overdone

11/10/2011 by Seeking Alpha
See More Articles...